Newsroom
Strive to Deliver Breakthroughs
-
November 15, 2024
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceuti...
View more -
November 08, 2024
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Cambridge, MA, Rotterdam, NL, Suzhou, CN – November 8, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutic...
View more -
October 10, 2024
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 9, 2024 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...
View more -
September 14, 2024
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
Cambridge, MA, Rotterdam, NL, Suzhou, CN — September 14, 2024 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...
View more -
August 28, 2024
Harbour BioMed Announces 2024 Interim Results
Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and c...
View more -
July 26, 2024
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
Cambridge, MA, Rotterdam, NL, Suzhou, CN — July 25, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
July 19, 2024
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 19, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
June 27, 2024
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 27, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
May 23, 2024
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) , a global biotechnology company providing a total solution from “Idea ...
View more -
March 28, 2024
Harbour BioMed Reports Full Year 2023 Financial Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN — March 28, 2024 Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharma...
View more
Copyright © 2024 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1